Clinical trials: Glucagon
Major Depressive Disorder
Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity
This 26-week long, double-blinded randomized clinical trial aims to investigate the effects of semaglutide once-weekly vs. placebo on depressive symptoms in 116 patients with Major Depressive Disorder (MDD) and co-existing…
- Trial name
- SEMAMOOD (NCT07136714)
- Testing
- Semaglutide Injectable Product
- Where
- Denmark
- Volunteers
- 116 people
- Sponsor
- Nordsjaellands Hospital
Hypoglycemia, Diabetes Mellitus, Type 1
A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DM
A randomized, double-blind, crossover trial to compare the efficacy and safety of 2 different batches of subcutaneous dasiglucagon in patients with type 1 diabetes mellitus (T1DM)
- Trial name
- NCT03895697
- Testing
- dasiglucagon
- Where
- Canada
- Volunteers
- 92 people
- Sponsor
- Zealand Pharma
Weight Maintenance
Assessing Follow up Trajectories in Eating, Routines, and Weight After GLP-1
Many people who use GLP-1 medications (such as semaglutide or tirzepatide) achieve meaningful weight loss, but maintaining that weight loss off after stopping the medication can be very challenging.
- Trial name
- AFTER-GLP (NCT07701460)
- Testing
- Digital Behavioral Application
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Tufts University
Glucose Metabolism, Glucagon
Investigating the Acute Effects of Increasing Glucagon Exposure in Healthy Participants
In this study the investigators will investigate the acute effects of increasing glucagon exposure on metabolic parameters in healthy participants. Participants will participate in one study day.
- Trial name
- NCT06921824
- Testing
- Glucagon
- Where
- Denmark
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Nicolai Jacob Wewer Albrechtsen
Healthy
Studies of the Early Meal Phase in Healthy Individuals - Nutrient Absorption and Gastrointestinal Hormone Secretion
To investigate gastrointestinal hormone secretions and nutrient absorption during the early meal phase we will recruit 12 healthy young men. They will be equipped with peripheral intravenous catheters for frequent blood sampling.
- Trial name
- NCT03543423
- Testing
- Oral glucose tolerance test, Liquid mixed meal test
- Where
- Denmark
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Cardiovascular Diseases
Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male Volunteers
The study seeks to explore the cardiovascular effects of co-agonism at two peptide receptors, GLP-1 and glucagon. Glucagon, exenatide and 0.9% saline will be intravenously infused, both in isolation, and combination into healthy…
- Trial name
- COCOA (NCT03835013)
- Testing
- Saline 0.9%, Glucagon (25ng/kg/min), Glucagon (50ng/kg/min)
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Bariatric Surgery (Gastric Bypass), Overweight
The Effect of Different Macronutrients on Gastrointestinal Hormone Secretion After Gastric Bypass Operation
The purpose of this study is to determine the type of macronutrient (carbohydrate, lipid or protein) that most potently stimulates the endogen secretion of different gut hormones (primary outcome = Glucagon-Like peptide-1) in…
- Trial name
- NCT02372526
- Testing
- Mealtest: High protein 200 kcal 200 ml liquid meal consumed during 10 minutes, Mealtest: High fat 200 kcal 200 ml liquid meal consumed during 10 minutes, Mealtest: High carbohydrate 200 kcal 200 ml liquid meal consumed during 10 minutes
- Where
- Denmark
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Kirstine Nyvold Bojsen-Moeller
Healthy
Study of Glucagon, Ghrelin and Growth Hormone as Counterregulatory Hormones
Glucagon has been used for decades as a test of growth hormone (GH) reserve. The pathway by which GH is stimulated by glucagon is not established.
- Trial name
- NCT01795235
- Testing
- Saline, Glucagon, Atenolol
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Gastric Emptying, Gastroparesis
Gastric Emptying Recovery After GLP-1 RA Cessation
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can delay gastric emptying and may increase residual gastric contents before general anesthesia.
- Conditions
- Gastric Emptying, Gastroparesis, Preoperative Care
- Trial name
- NCT07360262
- Testing
- Preoperative gastric ultrasound
- Where
- 2 sites in South Korea
- Volunteers
- 186 people
- Sponsor
- Wonkwang University Hospital
Type 2 Diabetes Mellitus
Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)
The primary objectives of this study are to determine if sitagliptin treatment is not inferior to that of glimepiride as measured by the change in baseline hemoglobin A1C (HbA1C) after 30 weeks of treatment, and if sitagliptin…
- Trial name
- NCT01189890
- Testing
- sitagliptin phosphate, Glimepiride
- Volunteers
- 480 people
- Sponsor
- Merck Sharp & Dohme LLC
Insulin Secretion, Insulin Resistance
Contribution of Pancreatic αcells Function to Blood Glucose Regulation in Chinese Type 2 Diabetics- the Effect of Sitagliptin on Glucagon Secretion, Insulin Secretion and Insulin Resistance in Chinese Type 2 Diabetics
1. The purpose of this study is to determine whether Sitagliptin therapy suppress glucagon release and improve glucose control in Chinese type 2 diabetic. 2.
- Trial name
- NCT01610154
- Testing
- Sitagliptin
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Guangwei Li
Type 2 Diabetes Mellitus
Endogenous Glucoseproduction in Patients With Type 2 Diabetes Mellitus During Oral Glucose and iv. Glucose Infusion
We want to investigate how lack of glucagon suppression during an oral glucose tolerance test in patients with type 2 diabetes contributes to patients postprandial hyperglycemia.
- Trial name
- EGP_Glucagon (NCT02010827)
- Testing
- isoglycemic intravenous glucose infusion and Glucagon infusion, day C, Oral glucose tolerance test, day A, intravenous iv glucose infusion, day B
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Diabetes Mellitus, Non-Insulin-Dependent
NNC 90-1170 Mechanism of Action: A Double-Blind, Randomized, Single-Center, Placebo-Controlled, Crossover Study to Examine Beta-Cell Responsiveness to Graded Glucose Infusion in Subjects With Type 2 Diabetes
The purpose of this research study is to investigate the mechanism of action of a new investigational medication (drug), NNC 90-1170, which is being developed for the treatment of type 2 diabetes (adult onset type of diabetes.
- Trial name
- NCT00013910
- Testing
- NNC 90-1170
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Center for Research Resources (NCRR)
Drug Discontinuation, Substance Use Disorders
Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation
The goal of this clinical study with research procedures is to learn how stopping and restarting tirzepatide (a medication that helps regulate blood sugar and appetite) affects brain activity, behavior, and health in adults ages…
- Conditions
- Drug Discontinuation, Substance Use Disorders, Eating Behavior Changes, Tirzepatide
- Trial name
- CLIN-GLP1 (NCT07387796)
- Testing
- Discontinuation and Reinitiation of Tirzepatide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- The University of Texas at Dallas
Type 2 Diabetes Mellitus
Diet Oil Induced Stimulation of GLP-1
Activation of G protein-coupled receptor GPR119 stimulates glucagon-like peptide-1 (GLP-1)release from the intestinal L-cells. Previously, administration of 2-oleyl-glycerol (2-OG) to humans significantly increased plasma GLP-1.
- Trial name
- NCT01453842
- Testing
- Diet oil, Olive oil, Carrot
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- University of Copenhagen
Diabetes Mellitus
Integration of Continuous Glucose Monitoring Into a BiHormonal Closed-Loop Artificial Pancreas
The investigators hypothesize that our closed-loop glucose-control system can provide BG control in subjects with type 1 diabetes using the estimated BG signal from a CGM as the input signal to the controller.
- Trial name
- CL2 (NCT01161862)
- Testing
- Bi-hormonal (insulin and glucagon) artificial pancreas
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Boston University Charles River Campus
Non-Alcoholic Fatty Liver Disease, Glucagon Resistance
The Effect of Lifestyle-induced Hepatic Steatosis on Glucagon-stimulated Amino Acid Turnover
Many patients with type 2 diabetes exhibit elevated plasma concentrations of the glucose-mobilising pancreatic hormone glucagon; i.e. hyperglucagonaemia.
- Trial name
- NCT04859322
- Testing
- Glucagon
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Malte Palm Suppli, MD
Irritable Bowel Syndrome Constipation Predominant
Effects of ROSE-010 on GI Transit in Constipation Predominant Irritable Bowel Syndrome (C-IBS) Patients
This trial will study the effects of an investigational (not FDA approved) medication, ROSE-010, on the movement of food through the stomach, small intestine and colon in females with constipation predominant irritable bowel…
- Trial name
- NCT01056107
- Testing
- ROSE-010
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Mayo Clinic
Hypoglycemia, Complications of Bariatric Procedures
Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients
The primary objective of this study is to test an optimized control system for sensor-guided (physician administered) delivery of glucagon, and test Proof-of-Concept (POC) in a clinical setting in patients with severe…
- Trial name
- NCT02733588
- Testing
- G-Pump™ (glucagon infusion)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Xeris Pharmaceuticals
Dementia, Mild, Mild Cognitive Impairment
Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)
The LIGHT-COG study is a 76-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial evaluating the efficacy and safety of mazdutide in 420 participants with type 2 diabetes (T2D) and…
- Conditions
- Dementia, Mild, Mild Cognitive Impairment, Type 2 Diabetes
- Trial name
- NCT07083154
- Testing
- Mazdutide
- Where
- 8 sites in China
- Volunteers
- 420 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School